Moreover, we demonstrate that KDM6A-mediated activation of TRKA is required for protection of CML cells against imatinib afforded by the neurotrophin nerve growth factor (NGF). This evidence concerns the gene KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive.